GlassScriptPhysician profile
Meredith Thompson Mitchell
NPI 1568018091
$1,839.30
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $712 · 2023: $242 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328 · Education: $85.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.86 |
| Education | $85.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.67 | 2021-2023 | |
| Novo Nordisk INC | $308.72 | 2021-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.17 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $154.37 | 2021-2023 | Mounjaro |
| Medtronic, INC. | $120.64 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $95.16 | 2021-2022 | |
| Amgen INC. | $92.62 | 2023-2024 | Repatha |
| Pfizer INC. | $69.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $53.90 | 2021 | |
| Astellas Pharma US INC | $41.98 | 2021-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.34 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $32.62 | 2022 | |
| Glaxosmithkline, LLC. | $26.97 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $26.42 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $22.91 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $22.72 | 2022 | |
| Daiichi Sankyo INC. | $17.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.58 | 2022 | |
| Eisai INC. | $15.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.29 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.12 | 2021 | |
| Esperion Therapeutics, INC. | $14.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.66 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.